PFE is set to double this year due to pipeline of "home run" drugs. And lets be honest here. PFE over the years has under performed and missed the stock market rally. But now it set to ramp higher as breast cancer drug pulls in more investors, Lipitor sales exceed expectations and analysts upgrade to "strong buy".
Oh should I also mention "baby boomer" getting up in age as health care stocks kick in big time.